Jason Keyes
Net worth: 367 236 $ as of 2026-05-30
Net worth: 367 236 $ as of 2026-05-30
Jason A. Keyes is currently an Independent Director at Actuate Therapeutics, Inc. since 2024.
Formerly, Mr. Keyes was Senior Director-Finance at Amylin Pharmaceuticals, Inc. from 2007 to 2013.
Served as Independent Director at Sesen Bio, Inc. from 2020 to 2023.
Held the position of Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc. from 2016 to 2018.
Worked at Amgen, Inc. as Head-Finance & Strategy.
Was Chief Financial Officer at Equillium, Inc. from 2018 to 2025.
Education includes undergraduate and graduate degrees from Stanford University and an MBA from UCLA Anderson School of Management.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EQUILLIUM, INC. 0.2% | 2025-02-13 | 126,633 ( 0.2% ) | 367 236 $ | 2026-05-30 |
| 2026-05-20 | 0 ( -.--% ) | - $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| ACTUATE THERAPEUTICS, INC. | Director/Board Member | 2024-08-11 |
| Companies | Position | End |
|---|---|---|
| EQUILLIUM, INC. | Director of Finance/CFO | 2025-04-24 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 2023-03-06 |
| OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 2018-02-22 |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Director of Finance/CFO | 2012-12-31 |
| AMGEN INC. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on the treatment of obesity | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sesen Bio, Inc.
Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
UCLA Anderson School of Management
UCLA Anderson School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel therapeutics which target cancers and neurodegenerative diseases | Health Technology |
Equillium, Inc.
Equillium, Inc. BiotechnologyHealth Technology Engages in the development of products for severe immune-inflammatory disorders | Health Technology |
Select your edition
All financial news and data tailored to specific country editions